Efforts to control prescription drug abuse: Why clinicians should be concerned and take action as essential advocates for rational policy

CA Cancer Journal for Clinicians

Volumn 64, Issue 6, 2014, Pages 369-376

  Twillman, Robert K ^a   Kirch, Rebecca ^b   Gilson, Aaron ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCODONE; LONG ACTING DRUG; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ABUSE DETERRENT FORMULATION; CANCER PAIN; CHRONIC PAIN; DRUG ABUSE; DRUG CONTROL; DRUG FORMULATION; DRUG INDICATION; DRUG MISUSE; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; INAPPROPRIATE PRESCRIBING; MEDICAL EDUCATION; MEDICINE CHEST; NOTE; PATIENT ADVOCACY; PHARMACY; PRESCRIPTION; PRESCRIPTION DRUG ABUSE; PRESCRIPTION DRUG DIVERSION; PUBLIC HEALTH PROBLEM; STORAGE; UNITED STATES; DRUG LABELING; HEALTH CARE PLANNING; POLICY; PREVENTION AND CONTROL; SUBSTANCE-RELATED DISORDERS;

ANALGESICS, OPIOID; DRUG LABELING; DRUG PRESCRIPTIONS; HEALTH RESOURCES; HUMANS; INAPPROPRIATE PRESCRIBING; PUBLIC POLICY; SUBSTANCE-RELATED DISORDERS;

EID: 84911443088     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21243     Document Type: Note

References (32)

1. Centers for Disease Control and Prevention. Prescription Painkiller Overdoses in the US. CDC Vital Signs. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
2. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses-a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012; 61: 10-13.
3. Hursh SR,. Behavioral economics of drug self-administration and drug abuse policy. J Exp Anal Behav. 1991; 56: 377-393.
4. Boyum D, Reuter P,. An Analytic Assessment of US Drug Policy. Washington, DC: AEI Press; 2005.
5. Physicians for Responsible Opioid Prescribing. Citizen Petition to Food and Drug Administration. regulations.gov/#!documentDetail;D=FDA-2012-P-0818-0001. Accessed May 15, 2014.
6. US Food and Drug Administration. Impact of Approved Drug Labeling on Chronic Opioid Therapy: Part 15 Hearing, Thursday, February 7, 2013. fda.gov/downloads/Drugs/NewsEvents/UCM342700.pdf. Accessed May 15, 2014.
7. US Food and Drug Administration. Impact of Approved Drug Labeling on Chronic Opioid Therapy: Part 15 Hearing, Friday, February 8, 2013. fda.gov/downloads/Drugs/NewsEvents/UCM342713.pdf. Accessed May 15, 2014.
8. US Food and Drug Administration. FDA CDER Response: Physicians for Responsible Opioid Prescribing Partial Petition Approval and Denial. regulations.gov/#!documentDetail;D=FDA-2012-P-0818-0793. Accessed May 15, 2014.
9. US Food and Drug Administration. FDA Briefing Document. January 24-25 Meeting Notes. Drug Safety and Risk Management Advisory Committee (DSaRM). fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisory-Committee/UCM337148.pdf. Accessed May 15, 2014.
10. US Food and Drug Administration. Summary Minutes of the Drug Safety and Risk Management Advisory Committee Meeting, January 24-25, 2013. fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM344674.pdf. Accessed May 15, 2014.
11. Drug Enforcement Administration. Schedules of controlled substances: rescheduling of hydrocodone combination products from Schedule III to Schedule II. Docket No. DEA-389. Fed Regist. 2014; 79: 11037-11045.
12. Leger DL,. Cardinal Health settles drug distribution case. USA Today. May 15, 2012 usatoday30.usatoday.com/news/health/story/2012-05-15/dea-cardinal-health-settlement/54981398/1. Accessed July 7, 2014.
13. Coleman JJ,. The supply chain of medicinal controlled substances: addressing the Achilles heel of drug diversion. J Pain Palliat Care Pharmacother. 2012; 26: 233-250.
14. Pauvik A,. Rx for danger: DEA blasts CVS for ignoring 'red flags' at Sanford stores. Orlando Sentinel. October 28, 2012 articles.orlandosentinel.com/2012-10-28/news/os-cvs-dea-oxycodone-ban-20121028-1-sanford-cvs-sanford-pharmacies-sanford-stores. Accessed July 7, 2014.
15. Leger DL,. Walgreens to pay $80 million for oxycodone violations. USA Today. June 11, 2013 usatoday.com/story/news/nation/2013/06/11/walgreens-drug-oxycodone-license-80-million/2412451/. Accessed July 7, 2014.
16. Drug Enforcement Administration. Knowing Your Customer/Suspicious Orders Reporting. deadiversion.usdoj.gov/chem-prog/susp.htm. Accessed May 15, 2014.
17. Segall B,. Walgreens' "secret checklist" reveals controversial new policy on pain pills. Name of Program. WTHR. March 11, 2014. wthr.com/story/23469086/2013/09/18/walgreens-secret-checklist-reveals-controversial-new-policy-on-pain-pills. Accessed July 7, 2014.
18. Buckley B, Buckley J,. Pharmacists feeling pain over restrictive AMA resolution. Pain Medicine News. August 2013.
19. Spears D,. Cancer patients being denied medications by pharmacists. Name of Program. KTNV television. May 15, 2014. Contact 13 Action News Story. jrn.com/ktnv/news/contact-13/contact-13-investigates/Patients-being-denied-medications-259444711.html. Accessed July 7, 2014.
20. Pri-Med. NCPA: Access to Controlled Substances Often Delayed. January 16, 2014. pri-med.com/PMO/MedicalNewsDetail.aspx?id=12208. Accessed May 15, 2014.
21. Buckley B,. Pharmacists Turn Away Legitimate Pain Patients as Wholesalers Limit Shipments of Controlled Substances. pharmacist.com/pharmacists-turn-away-legitimate-pain-patients-wholesalers-limit-shipments-controlled-substances-0. Accessed May 15, 2014.
22. Balko R,. Painkiller access debated as patients suffer. The Huffington Post. March 9, 2012:Pages. huffingtonpost.com/radley-balko/painkiller-access-debated-b-1332511.html. Accessed May 15, 2014.
23. US Food and Drug Administration. Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Access date.
24. Cicero TJ, Ellis MS, Surratt HL,. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012; 367: 187-189.
25. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health. samhsa.gov/data/NSDUH.aspx. Accessed March 28, 2014.
26. Drug Enforcement Administration. Disposal of Controlled Substances. Docket No. DEA-316. deadiversion.usdoj.gov/fed-regs/rules/2012/fr1221-8.htm. Accessed June 15, 2014.
27. Office of National Drug Control Policy. National Drug Control Strategy. whitehouse.gov/sites/default/files/ondcp/ndcs2011.pdf. Accessed June 15, 2014.
28. McDonald DC, Carlson KE,. Estimating the prevalence of opioid diversion by "doctor shoppers" in the United States. PLoS One. 2013; 8: e69241.
29. National Alliance for Model State Drug Laws. States That Require Prescribers and/or Dispensers to Access PMP Database in Certain Circumstances. namsdl.org/library/242A95B2-1C23-D4F9-746603F15D8BA24B/. Accessed May 15, 2014.
30. Room R, Reuter P,. How well do international drug conventions protect public health? Lancet. 2012; 379: 84-91.
31. Pain and Policy Studies Group. Achieving Balance in State Pain Policy: A Progress Report Card. CY 2013 ed. Madison, WI: University of Wisconsin Carbone Cancer Center; 2014.
32. Pain and Policy Studies Group. Achieving Balance in Federal and State Pain Policy: A Guide to Evaluation. CY 2013 ed. Madison, WI: University of Wisconsin Carbone Cancer Center; 2014.